Investigational Products

[F-18]-DCFPyL Injection

[F-18]-DCFPyL Injection is a novel, urea-based, small molecule imaging biomarker that targets prostate-specific membrane antigen (PSMA).  PSMA is overexpressed in prostate cancer, particularly in poorly differentiated, hormone-independent and metastatic disease; this makes PSMA a useful target in patients with more aggressive forms of prostate cancer.

In combination with positron emission tomography (PET), [F-18]-DCFPyL has potential as a tool to guide treatment planning, predict treatment response and inform about the prognosis in patients with primary and metastatic prostate cancer.


Maurer T, Eiber M, Schwaiger M et al. Current use of PSMA-PET in prostate cancer management. Nature Reviews Urology. 2016; 13(4): 226-235.

Szabo Z, Mena E, Rowe SP et al. Initial Evaluation of 18F-DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015; 17(4): 565-574.

Dietlein M, Kobe C, Kuhnert G et al. Comparison of 18F-DCFPyL and 68Ga-PSMA-HBED-CC for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015; 17(4): 575-584.

These references are provided for informational purposes only and do not represent an endorsement for any particular clinical use.